Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

993.95 +6.68 (+0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 331,611
Open 987.99
Bid (Size) 994.20 (2)
Ask (Size) 1,002.00 (1)
Prev. Close 987.27
Today's Range 982.97 - 995.92
52wk Range 684.80 - 998.33
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets

Performance

YTD
+9.83%
+9.83%
1 Month
+10.42%
+10.42%
3 Month
+4.97%
+4.97%
6 Month
+24.43%
+24.43%
1 Year
+32.26%
+32.26%

More News

Read More
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
From Kirby McInerney LLP
Via Business Wire
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Via The Motley Fool
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
Via Benzinga
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Week Of May 13, 2024: What's In Store For The Markets
Via Talk Markets
Healthcare And Biotech Investing 101: What You Need To Know.
Via Talk Markets
Topics Stocks
Exposures US Equities
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sell In May? No Way!
Via Talk Markets
Will the Biotech Sector Shift From Lagger to Leader?
Via MarketBeat
Topics ETFs
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Via InvestorPlace
Exposures Product Safety
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
Via InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Via Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.